TransMedics Group (NASDAQ:TMDX) Sees Large Volume Increase - Time to Buy?

TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) shares saw strong trading volume on Wednesday . 464,930 shares were traded during mid-day trading, a decline of 49% from the previous session's volume of 912,090 shares.The stock last traded at $84.17 and had previously closed at $88.50.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. Oppenheimer dropped their target price on TransMedics Group from $200.00 to $125.00 and set an "outperform" rating on the stock in a research report on Tuesday. Baird R W upgraded TransMedics Group to a "strong-buy" rating in a research report on Tuesday, September 24th. Morgan Stanley increased their target price on TransMedics Group from $104.00 to $145.00 and gave the company an "equal weight" rating in a research report on Monday, July 15th. Piper Sandler reissued an "overweight" rating and issued a $180.00 price target on shares of TransMedics Group in a research note on Tuesday. Finally, Canaccord Genuity Group reduced their price objective on shares of TransMedics Group from $169.00 to $109.00 and set a "buy" rating for the company in a research report on Tuesday. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $144.80.

TransMedics Group Trading Down 7.4 %

The company has a current ratio of 9.37, a quick ratio of 8.48 and a debt-to-equity ratio of 2.67. The company has a fifty day moving average price of $146.02 and a two-hundred day moving average price of $140.16. The firm has a market capitalization of $2.73 billion, a price-to-earnings ratio of 90.30 and a beta of 1.99.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings data on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing analysts' consensus estimates of $0.29 by ($0.17). TransMedics Group had a return on equity of 15.98% and a net margin of 0.84%. The company had revenue of $108.76 million for the quarter, compared to analyst estimates of $115.00 million. During the same period last year, the firm posted ($0.12) EPS. The business's quarterly revenue was up 63.7% on a year-over-year basis. As a group, research analysts forecast that TransMedics Group, Inc. will post 1.22 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Waleed H. Hassanein sold 8,625 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the completion of the transaction, the chief executive officer now directly owns 61,643 shares in the company, valued at approximately $9,457,269.06. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $153.42, for a total value of $1,323,247.50. Following the completion of the sale, the chief executive officer now owns 61,643 shares in the company, valued at approximately $9,457,269.06. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Tamer I. Khayal sold 2,958 shares of the company's stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $156.77, for a total value of $463,725.66. Following the transaction, the insider now owns 20,843 shares in the company, valued at $3,267,557.11. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 64,205 shares of company stock valued at $9,981,907 in the last 90 days. Company insiders own 7.00% of the company's stock.

Hedge Funds Weigh In On TransMedics Group

Several institutional investors have recently bought and sold shares of TMDX. Vanguard Group Inc. grew its stake in TransMedics Group by 2.8% during the 4th quarter. Vanguard Group Inc. now owns 1,865,115 shares of the company's stock worth $147,214,000 after purchasing an additional 50,673 shares in the last quarter. Allspring Global Investments Holdings LLC grew its position in shares of TransMedics Group by 3.1% during the first quarter. Allspring Global Investments Holdings LLC now owns 730,010 shares of the company's stock worth $53,977,000 after buying an additional 21,737 shares in the last quarter. Oak Ridge Investments LLC increased its stake in shares of TransMedics Group by 59.5% during the first quarter. Oak Ridge Investments LLC now owns 18,267 shares of the company's stock worth $1,351,000 after buying an additional 6,813 shares during the period. BNP Paribas Financial Markets raised its holdings in TransMedics Group by 35.1% in the first quarter. BNP Paribas Financial Markets now owns 17,390 shares of the company's stock valued at $1,286,000 after acquiring an additional 4,518 shares in the last quarter. Finally, Fidelis Capital Partners LLC purchased a new position in TransMedics Group in the first quarter worth approximately $35,000. 99.67% of the stock is owned by institutional investors and hedge funds.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.